Alzheimer disease and its management: A review

American Journal of Therapeutics

Volumn 13, Issue 6, 2006, Pages 516-526

  Samanta, Malay K ^a   Wilson, B ^a   Santhi, K ^a   Sampath Kumar, K P ^a   Suresh, B ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer disease; NMDA receptor antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMYLOID; ANTIOXIDANT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; DICLOFENAC; DONEPEZIL; ERYTHROMYCIN; ESTROGEN; FLUVOXAMINE; GALANTAMINE; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; KETOCONAZOLE; LEVACECARNINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PREDNISONE; PROGESTERONE; RISPERIDONE; RIVASTIGMINE; ROFECOXIB; STATINE DERIVATIVE; TACRINE;

AGING; ALZHEIMER DISEASE; AREA UNDER THE CURVE; CAR DRIVING; CAREGIVER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COOKING; DEGENERATIVE DISEASE; DELIRIUM; DEMENTIA; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; INSOMNIA; LIVER TOXICITY; MONEY; NAUSEA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOSIS; PURPURIC RASH; RESTLESS LEGS SYNDROME; REVIEW; SENILE PLAQUE; STUTTERING; SYMPTOMATOLOGY; TELEPHONE; UNITED STATES; URINE INCONTINENCE; VOMITING;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GALANTAMINE; HISTORY, 20TH CENTURY; HUMANS; INDANS; MEMANTINE; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; TACRINE;

EID: 33751379574     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000208274.80496.f1     Document Type: Review

References (117)

1. Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Can Med Assoc J. 2003;169:557-564.
2. Mahoney JM. Alzheimer's disease: pharmacologic management and clinical update. ASHP Annual Meeting. 1991;48:1-6.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: The Association; 2000.
4. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease affected brain: presence of oligomeric Aβ ligands (ADDLS) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417-10422.
5. Reichman WE. Current pharmacologic options for patients with Alzheimer's disease. Available at: http://www.general-hospital-psychiatry.com/content/2/1 [Accessed June 15, 2004].
6. American Health Assistance Foundation. Available at: http://www.ahaf.org/ alzdis/about/adhistory.htm [Accessed May 5, 2005].
7. Autuono P, Beyer J. The burden of dementia. A medical and research perspective. Theor Med Bioeth. 1999;20:3-13.
8. Alzheimer's Association. Available at: http://www.alz.org/AD/statistics. htm [Accessed November 11, 2003].
9. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer's disease in the US population: prevalence estimates using 2000 census. Arch Neurol. 2003;60:1119-1122.
10. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990;68:267-289.
11. Canadian Study of Health and Aging Work Group. Canadian study of health and aging: study methods and prevalence of dementia. CMAF. 1994;150:899-913.
12. The incidence of dementia in Canada. The Canadian study of Health and Aging Working Group. Neurology. 2000;55:66-73.
13. Fillit H, Hill JW, Fufferman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med. 2002;34:528-535.
14. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. DSM-IV. Washington, DC: American Psychiatric Association; 1994.
15. Mc Khan G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:339-344.
16. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer's disease and related disorders. Consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's association and the American Geriatric Society. JAMA. 1997;278:1363-1371.
17. Knopman DS, De Kosky S, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
18. Cummings JL. Alzheimer's disease. N Eng J Med. 2004;351:56-57.
19. Kawas CH. Early Alzheimer's disease. N Eng J Med. 2003;349:1056-1063.
20. Selkoe DJ. The origins of Alzheimer's disease: a is for amyloid. JAMA. 2000;283:1615-1617.
21. Spillantini MG, Goedert M. The protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21:428-433.
22. Golde TE. Alzheimer's disease therapy: can the amyloid cascade be halted? J Clin Invest. 2003;11:11-18.
23. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
24. Roses AD, Strittmatter WJ, Pericak-Vance MA, et al. Clinical applications of apolipoprotein E genotyping to Alzheimer's disease. Lancet. 1994;343:1564-1565.
25. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding ole in cell biology. Science. 1998;240:622-630.
26. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Eng J Med. 1996;334:752-758.
27. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Eng J Med. 1995;333:1242-1247.
28. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383-421.
29. Standaert DG, Young AB. Treatment of central nervous system. degenerative disorders. In: Hardman JG, Limbard LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: Mc Graw-Hill; 2001:560.
30. Green JD, Baddelay AD, Hodges JR. Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia. 1996;34:537-551.
31. Price BH, Gurvit H, Weintraub S, et al. Neuropsychological patterns and language deficits in 20 consecutive cases of autopsy-confirmed Alzheimer's disease. Arch Neurol. 1993;50:931-937.
32. Kirk A, Kertesz A. On drawing impairment in Alzheimer's disease. Arch Neurol. 1991;48:73-77.
33. Available at: http://www.medicinenet.com/Alzheimer's_Disease/page4.htm [Accessed November 11, 2003].
34. Etienne P, Dastor D, Gauthier S, et al. Alzheimer's disease: lack of effect of lecithin treatment for three months. Neurology. 1981;31:1552-1554.
35. Thal LJ, Rosen W, Sharpless NS, et al. Choline chloride fails to improve cognition of Alzheimer's disease. Neurobiol Aging. 1981;2:205-208.
36. Gray JA, Enz A, Spiegel R. Muscaranic agonists for senile dementia: past experience and future trends. Trends Pharmacol Sci. 1989;10:85-88.
37. Bodick NC, Offen WW, Levey AI, et al. The effect of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in Alzheimer's disease. Arch Neurol. 1997;54:465-473.
38. Bartus RT, Dean RL, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-417.
39. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Eng J Med. 1999;341:1670-1679.
40. Kumar V, Becker RE. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent for Alzheimer's disease. Int J Cli Pharmacol Ther Toxicol. 1989;27:478-485.
41. Freeman SE, Dawson RM. Tacrine: a pharmacological review. Prog Neurobiol. 1991;36:257-277.
42. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicentre study of tacrine for Alzheimer's disease. The collaborative study group. N Eng J Med. 1992;327:1253-1259.
43. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. The tacrine study group. JAMA. 1992;268:2523-2529.
44. Solomon PR, Knapp MJ, Gracon SI, et al. Long-term tacrine treatment in patients with Alzheimer's disease. Lancet. 1996;348:275-276.
45. Hartvig P, Askmark H, Aquilonius SM, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Cli Pharmacol. 1990;38:259-263.
46. Welty DF, Siedlik PH, Posvar EL, et al. Temporal effect of food on tacrine bioavailability. J Clin Pharmacol. 1994;34:985-988.
47. Forgue ST, Reece PA, Sedman AJ, et al. Inhibition of tacrine oral clearance by cimitedine. Clin Pharmacol Ther. 1996;59:444-449.
48. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther. 1997;61:619-627.
49. Watkins PB, Zimmerman HJ, Gamzu ER, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 1994;271:992-998.
50. Ford JM, Truman CA, Wilcock GK, et al. Serum concentration of tacrine hydrochloride predicts its adverse effects in Alzheimer's disease. Clin Pharmacol Ther. 1993;53:691-695.
51. NDTI (Diagnosis code: 3310, 2900, 2901, 2902, 2903, 2904, 3109, 2912), Moving Annual Total (MAT) July 2001.
52. Mohs RC, Doody RS, Morris JC, et al. A 1-year placebo controlled preservation of function. Survival study of donepezil in Alzheimer's disease patients. Neurology. 2001;57:481-488.
53. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate Alzheimer's disease. Neurology. 2001;57:489-495.
54. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:295-300.
55. Goldsmith DR, Scott LJ. Donepezil - in vascular dementia. Drugs Aging. 2003;20:1127-1136.
56. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia-positive results of a 24-week, multicentre, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323-2330.
57. Steuer M, Chauvel O, Dauchot A, et al. Efficacy of donepezil's treatment in dementia with Lewy bodies. J de Pharm Clin. 2003;22:155-158.
58. Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother. 2001;35:202-205.
59. Laird RD, Webb M. Psychotic episode during use of St. Johns Wort. J Herb Pharmacother. 2001;1:81-87.
60. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer's disease: a 15 week, double blind, placebo controlled. study. Donepezil study group. Arch Intern Med. 1998;158:1021-1031.
61. Burns A, Rossor M, Hecker J, et al. The effect of. donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237-244.
62. Amouyal-Barkate K, Bagheri-Charabiani H, Montastruc JL, et al. Abnormal movements with donepezil in Alzheimer's disease. Ann Pharmacother. 2000;34:1347.
63. Hashimoto M, Imamura T, Tanimukai S, et al. Urinary incontinence: unrecognized adverse effect with donepezil. Lancet. 2000;356:568.
64. Bryant CA, Ouldred E, Jackson SH. Purpuric rash with donepezil treatment. BMJ. 1998;317:787.
65. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41:719-739.
66. Williams BR, Nazarians A, Gill MA. A review of Rivastigmine: a reversible cholinesterase inhibitor. Clin Ther. 2003;25:1634-1653.
67. Nordberg A, Svensson AL. Cholinergic inhibitors in the treatment of Alzheimer's disease a comparison of tolerability and pharmacology. Drug Safety. 1998;19:465-480.
68. Arendt T, Bruckner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinestease in Alzheimer's disease resemble embryonic development - a study of molecular forma. Neurochem Int. 1992;21:381-396.
69. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol. 2002;47:64-70.
70. Roesler M, Klein HE, Ackenheil M. An open study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. Presentation at ACNP, Puerto Rico, December 2002.
71. Kaasinen V, Nagren K, Jarvenpaa T, et al. Regional effects of donepezil and rivastigmine on brain acetylcholinesterase are greater in the frontal cortex compared to the temporal cortex in Alzheimer's disease. J Clin Pharmacol. 2002;22:615-620.
72. Auriacombe S, Vellas B, Pere J-J, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. CMRO. 2002;18:129-138.
73. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18:258-264.
74. Mc Keith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: randomized, double blind, placebo controlled international study. Lancet. 2000;365:2031-2036.
75. Gabelli C. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr Med Res Opin. 2003;19:69-82.
76. Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res. 1998;23:787-794.
77. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The galantamine USA-10 study group. Neurology. 2000;54:2269-2276.
78. Wilcock GK, Lilienfeid S, Gaens E, et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicenter randomized controlled trial. BMJ. 2000;321:1445-1449.
79. Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003;25:1765-1782.
80. Small GW, Erkinjuntti T, Kurz A, et al. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs. 2003;17:905-914.
81. Migliaccio-Walle K, Getsios D, Caro JJ, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther. 2003;25:1806-1825.
82. Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors - a guide to neurologists. CNS Drugs. 2003;17:947-963.
83. Huang FL, Lasseter KC, Janssens L, et al. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administred alone and together. J Clin Pharmacol. 2002;42:1341-1351.
84. Mac-Gowan SH, Wilcock G, Scott M. Effect of gender and apolipoprotein E genotype on response to acetylcholinesterase therapy in Alzheimer's disease. Int J Geri Psychiatr. 1998;13:625-630.
85. Farlow MR, Lahiri DK, Poirer J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and the gender of the subjects with Alzheimer's disease. Neurology. 1998;50:669-677.
86. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacol. 1999;38:735-767.
87. Jarvis B, Figgitt DP. Memantine. Drugs Aging. 2003;20:465-476.
88. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil - a randomized controlled trial. JAMA. 2004;291:317-324.
89. Gortelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome: double-blind placebo-controlled study. Arzneimittel- Forschung. 1992;42:904-913.
90. Wimo A, Winblad B, Stoffler A, et al. Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21:327-340.
91. Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA receptor antagonist memantine in patients with chronic limb pain-results of a randomized double-blinded, placebo controlled trial. Pain. 2003;103:277-283.
92. Grossmann W, Schutz W. Memantine and neurogenic bladder dysfunction in spastic conditions. Arzneimittelforschung. 1982;32:1273-1276.
93. Rabey JM, Nissiperau P, Korezyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm. 1992;4:277-282.
94. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology. 1997;48:36-41.
95. Tang MX, Jacobs D, Stern Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
96. Yoon BK, Kim DK, Kang Y, et al. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. Fertil Steril. 2003;79:274-280.
97. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2005;54:295-301.
98. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. JAMA. 2000;283:1007-1015 [Erratum, JAMA. 2000;284:2597].
99. Shumaker Sa, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and cognitive impairment in postmenopausal women: the women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
100. Finch CE, Longo V, Miyao A, et al. Inflammation and Alzheimer's disease. In: Chesselet M-F, ed. Molecular Mechanisms of Neurodegenerative Disorder. Totowa, N.J: Humana Press; 2001:87-110.
101. Breitner JC. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu Rev Med. 1996;47:401-411.
102. Stewart WJ, Kawas C, Corrada M, et al. Risk of Alzheimer's disease and duration of NSAID use. Neurol. 1997;48:626-632.
103. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 2000;54:588-593.
104. Seharf S, Mander A, Ugoni A, et al. A double blind, placebo controlled trial of diclofenac/misoprostal in Alzheimer's disease. Neurology. 1999;53:7-201.
105. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
106. 42 in vivo. J Clinical Invest. 2003;112:440-449; doi: 10.1172/JCI 2003 18162.
107. Halliwell B, Gutteridge JMC. Oxygen radicals in the nervous system. Trends Neurosci. 1985;8:22-26.
108. Behl C, Sagara Y. Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspectives. J Neural Transm Suppl. 1997;49:125-134.
109. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Eng J Med. 1997;336:1216-1222.
110. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA. 2002;287:3223-3229.
111. Esposito E, Rotilio D, Di Matteo V, et al. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging. 2002;23:719-735.
112. Spagnoli A, Lucca U, Menasce G, et al. Long term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology. 1991;41:1726-1732.
113. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levo carnitine in patients with Alzheimer's disease. Arch Neurol. 1992;49:1137-1141.
114. Bianchetti A, Rozzini R, Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin. 2003;19:350-353.
115. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs. 2002;16:811-824.
116. Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19:707-714.
117. Taylor AM, Hoehns JD, Anderson DM, et al. Fatal aspiration pneumonia during transition from donepezil to Rivastigmine. Ann Pharmacother. 2002;36:1550-1553.